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Mitochondrial disorders are highly heterogeneous
conditions characterized by defects of the mitochon-
drial respiratory chain. Pharmacological activation of
mitochondrial biogenesis has been proposed as an
effective means to correct the biochemical defects
and ameliorate the clinical phenotype in these
severely disabling, often fatal, disorders. Pathways
related to mitochondrial biogenesis are targets of
Sirtuin1, a NAD+-dependent protein deacetylase. As
NAD+ boosts the activity of Sirtuin1 and other sirtuins,
intracellular levels of NAD+ play a key role in the
homeostatic control of mitochondrial function by the
metabolicstatusof thecell.Weshowhere thatsupple-
mentation with nicotinamide riboside, a natural NAD+
precursor, or reduction of NAD+ consumption by in-
hibiting the poly(ADP-ribose) polymerases, leads to
marked improvement of the respiratory chain defect
and exercise intolerance of the Sco2 knockout/
knockin mouse, a mitochondrial disease model char-
acterized by impaired cytochrome c oxidase bio-
genesis. This strategy is potentially translatable into
therapy of mitochondrial disorders in humans.
INTRODUCTION
Primary mitochondrial disorders due to impaired oxidative phos-
phorylation (OXPHOS) are a well-established cause of severe
disability and precocious death in both children and adults
(Koopman et al., 2012). No effective therapies are currently avail-
able for these conditions, but encouraging results have recently
been obtained by stimulatingmitochondrial biogenesis acting on
either the PPAR system (Wenz et al., 2008) or the AMP-kinase1042 Cell Metabolism 19, 1042–1049, June 3, 2014 ª2014 The Autho(AMPK)/PGC1a axis (Viscomi et al., 2011). Importantly, these ap-
proaches can in principle be extended to several mitochondrial
diseases with different genetic causes, as they do not point to
the correction of a specific defect but are based on a more gen-
eral strategy aimed at increasing the overall residual activity of
the respiratory chain.
Additional targets able to activate the mitochondriogenic
program and boost mitochondrial function are sirtuins 1–7
(Houtkooper et al., 2012), the mammalian orthologs of the yeast
silent information regulator (Sir) 2 gene (Imai et al., 2000; Vaziri
et al., 2001). Sirtuins have different subcellular localization,
Sirt1 and Sirt6 being mainly found in the nucleus, Sirt2 in the
cytosol, Sirt3–Sirt5 in mitochondria, and Sirt7 in the nucleolus.
Sirtuins are important regulators of several proteins, including
key metabolic players, acting as either deacetylases or ADP-
ribosylases (Houtkooper et al., 2012). The most-investigated
member of the family is Sirtuin1 (Sirt1), a NAD+-dependent
type III nuclear deacetylase that utilizes NAD+ as a cosubstrate
to remove acetyl groups from lysine residues of a target protein.
Known targets of Sirt1 are the tumor suppressor p53, the myo-
cyte-specific enhancer factor 2 (MEF2), the Forkhead box O
(FOXO), and PGC1a, all of which regulate transcriptional pro-
grams related to increased mitochondrial function (Andreux
et al., 2013). Sirt1 activity is directly regulated by NAD+ availabil-
ity, by substrate-dependent activation, raising the hypothesis
that NAD+ acts as a metabolic sensor. For instance, both
NAD+ levels and Sirt1 activity increase in mammalian tissues in
response to energy/nutrient stresses such as exercise (Canto´
and Auwerx, 2009, 2010) and fasting (Canto´ and Auwerx,
2010; Chen et al., 2008; Rodgers et al., 2005). Recent studies
have shown that Sirt1 activation can prevent diet-induced
obesity in mice. This effect was achieved by increasing the con-
tent of NAD+ in cells and tissues essentially through (1) dietary
supplementation of suitable NAD+ precursors, such as Nicotin-
amide Riboside, NR (Canto´ et al., 2012), or (2) inhibition of
NAD+-consuming enzymes, such as the poly(ADP-ribose) poly-
merase 1, PARP1 (Bai et al., 2011). Here, we have tested thers
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Figure 1. Characterization of Parp1–/–-Sco2KOKI Double Mutants
(A) Treadmill analysis of motor performance. Solid black, WT; dashed black, Parp1/; solid red, Sco2KOKI; dashed red, Parp1/-Sco2KOKI. The asterisks
represent the significance levels calculate by unpaired, two-tailed Student’s t test; ***p < 0.001.
(B) MRC activities (nmoles/min/mg of protein) in skeletal muscle. Solid black, WT; black outline, Parp1/; solid red, Sco2KOKI; red outline, Parp1/-Sco2KOKI.
CS, citrate synthase; CI-IV, MRC complexes I–IV. Error bars represent the standard deviation (SD). Unpaired, two-tailed Student’s t test; *p < 0.05; **p < 0.01;
***p < 0.001.
(C) COX staining in skeletal muscle of WT (Ca), Parp1/ (Cb), Sco2KOKI (Cc), and Sco2KOKI-Parp1/mice (Cd). Note the increased COX staining in the double
mutants. Scale bar, 100 mm.
(D) MRC activities in the brain. Color codes as in (B). Error bars represent the standard deviation (SD). Unpaired, two-tail Student’s t test; **p < 0.01;
***p < 0.001.
(E) COX staining in the brain of WT (Ea), Parp1/ (Eb), Sco2KOKI (Ec), and Sco2KOKI-Parp1/ mice (Ed). Scale bar, 100 mm.
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In Vivo Correction of COX Deficiency by Sirt 1therapeutic efficacy of these strategies on a genetic mitochon-
drial disease model, the Sco2 knockout/knockin (Sco2KOKI)
mouse (Yang et al., 2010). Sco2 encodes a metallochaperone
involved in the formation of the copper redox centers into
nascent complex IV (cytochrome c oxidase, COX) (Leary et al.,
2009). Mutations in this gene lead to infantile fatal encephalo-
cardiomyopathy (Papadopoulou et al., 1999). Most of the pa-
tients carry at least one allele encoding the common mutation
p.E140K, corresponding to the p.E129K mutation in the knockin
murine Sco2 allele. The second knockout allele in this animal
model is functionally null (Yang et al., 2010). While homozygous
knockout individuals are embryonic lethal, the Sco2KOKI mice
show a predominantly myopathic phenotype characterized
by exercise intolerance and associated with ubiquitous COX
deficiency.
RESULTS
Ablation of PARP1 Improves Motor Performance in
Sco2KOKI Mice
To test the effects of persistent increase of the NAD+ pool
on the Sco2KOKI mouse, we first crossed it with a constitu-
tive Parp1/ mouse (de Murcia et al., 1997), which showsCell Mincreased levels of NAD+ in skeletal muscle (Bai et al., 2011).
The Sco2KOKI-Parp1/ double mutants showed reduced fast-
ing blood glucose levels, body weight and epididymal white ad-
ipose tissue (WAT) compared to Sco2KOKI littermates, whereas
no differences were observed between WT and Parp1/ litter-
mates (see Figure S1 available online). The endurance motor
performance of Sco2KOKI-Parp1/ double mutants, Sco2KOKI,
Parp1/, and WT littermates (four animals per group) was
monitored weekly by a standard treadmill test for 4 weeks start-
ing at 2 months of age. While Sco2KOKI mice showed markedly
reduced motor performance compared to WT littermates
throughout the observation time, the double mutant individuals
performed as well as the WT and Parp1/ littermates (Fig-
ure 1A). Biochemically, significant reduction of complex IV ac-
tivity and, to a lesser extent, complex III as well (Yang et al.,
2010), was measured in skeletal muscle of Sco2KOKI mice. In
the muscle homogenate of Sco2KOKI-Parp1/ double mutants,
these activities were comparable to that of Parp1/ and WT lit-
termates, whereas complex I and II activities were even higher
(Figure 1B; Table S1). Accordingly, the intensity of the histo-
chemical staining specific to COX was increased in skeletal
muscle of the double mutants, compared to the Sco2KOKI mu-
tants (Figure 1C). The activities of complex III and IV (Figure 1D;etabolism 19, 1042–1049, June 3, 2014 ª2014 The Authors 1043
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relative to Sco2KOKI animals, but remained significantly lower
than those measured in Parp1/ and WT littermates; the histo-
chemical reaction to COX was concordant with the biochemical
data (Figure 1E).
NR IncreasesMotor Performance and InducesOXPHOS-
Related Gene Expression in Sco2KOKI Skeletal Muscle
To test the effects of pharmacological intervention, we first
administered NR to Sco2KOKI mice and WT littermates (n = 4/
group), as a food admix (400 mg/Kg) (Canto´ et al., 2012) for
four weeks. Metabolic parameters in the treated groups,
including reduced blood glucose, plasma fatty acids, and
epididymal WAT, mirrored those of Parp1/ mice (Figure S2),
confirming that NR, or its derivative NMN, was pharmacologi-
cally active in vivo. NR-treated Sco2KOKI mice significantly
improved their motor performance compared to the vehicle-
treated Sco2KOKI group, rapidly achieving the levels of motor
endurance displayed by treated and untreated WT mice (Fig-
ure 2A), which showed no difference to each other. These
results suggest that NR treatment increases mitochondrial
function in the Sco2KOKI mice through NAD+ activation of Sirt1
(Canto´ et al., 2012). Accordingly, the NAD+/NADH ratio was
significantly increased (Figure 2B), and the ratio between acet-
ylated and total FOXO1, a direct target of Sirt1, was clearly
reduced (Figure 2C) in skeletal muscle of NR-treated versus
vehicle-treated Sco2KOKI and WT animals. We did not observe
differences in mtDNA content (data not shown) and citrate syn-
thase (CS) activity (Figure 2F), but mRNA levels of several genes
related to either fatty acids oxidation (FAO), including ACOX
and CD36, or oxidative phosphorylation (COXI, COXII, COXIV,
COXVa) were significantly increased in NR-treated versus
vehicle-treated Sco2KOKI but not in WT animals (Figure 2D).
TFAM, a key factor of mtDNA transcription, was also increased,
and UCP3 and PDK4, which were downregulated in Sco2KOKI
mice, returned to control levels upon NR treatment. As ex-
pected, we found no change in transcripts specific to PGC1a,
which is activated posttranscriptionally by Sirt1, and to two
PGC1a partners, NRF1 and NRF2. Accordingly, western blot
immunovisualization demonstrated increased levels of several
nuclear- and mitochondrial-DNA-encoded OXPHOS-related
proteins in NR-treated versus vehicle-treated skeletal muscle
samples (Figure 2E). In the same specimens, mitochondrial
respiratory chain activities were significantly increased (Fig-
ure 2F; Table S3) in NR-treated versus vehicle-treated Sco2KOKI
mice, but not in WT animals. The histochemical staining for COX
reflected the biochemical results (Figure 2G).
In both C. elegans and mammalian cells, NR-dependent Sirt1
activation can induce the mitochondrial unfolded protein
response (mtUPR), a stress-response protective mechanism
which can improve mitochondrial function (Durieux et al.,
2011; Mouchiroud et al., 2013). We found that the mtUPR-spe-
cific transcripts Clpp, Hsp60, and Sod2 were significantly
increased in muscle samples of NR-treated Sco2KOKI mice,
whereas Sod3, which is unrelated to mtUPR, was unchanged
(Figure 2H).
No effect of the NR treatment was observed on the mito-
chondrial respiratory chain activities in the brain of our animals
(Table S4).1044 Cell Metabolism 19, 1042–1049, June 3, 2014 ª2014 The AuthoPARP1 Inhibitors Induce Mitochondrial Function in
Skeletal Muscle and Brain
Next, we administered a pan-PARP inhibitor (MRLB-45696, IC50
for PARP < 1 nM; Pirinen et al., 2014, in this issue of Cell Meta-
bolism) at 50 mg/Kg as a food admix for 4 weeks. In MRLB-
45696-treated Sco2KOKI mice, we observed metabolic effects
similar to those of NR treatment (Figure S3). Weekly treadmill
tests showed progressive increase, up to normal, of the motor
endurance in MRLB-45696-treated Sco2KOKI, whereas no
change was seen in WT mice (Figure 3A). The NAD+/NADH ratio
was significantly increased in treated versus untreated WT, but
not in the Sco2KOKI, animals (Figure 3B), whereas the acety-
lated/total FOXO1 ratio was reduced in both treated groups
(Figure 3C), indicating activation of Sirt1 by MRLB-45696.
Similar to NR, MRLB-45696 increased the mRNA expression
levels of OXPHOS- and FAO-related genes in both Sco2KOKI
and WT mice, whereas mtDNA content (data not shown) and
CS activity (Figure 3F) remained unchanged. In treated Sco2KOKI
but not in WT animals, western blot analysis showed increased
content of mitochondrial respiratory chain subunits (Figures 3D
and 3E), which was paralleled by significantly increased mito-
chondrial respiratory chain activities (Figure 3F; Table S3). Histo-
chemistry for COX showed increased staining in treated versus
vehicle-treated Sco2KOKI mice (Figure 3G). Again, we found
that expression of the mtUPR genes Hsp60, Clpp, and Sod2
was significantly increased, unlike the mtUPR-unrelated gene
Sod3 (Figures 3H and 3I).
In contrast to the NR treatment, the MRLB-45696 treatment
determined significant increase of COX transcripts (Fig-
ure 4A), and respiratory chain activities in the brain (Figure 4B;
Table S4). The intensity of COX staining was increased as well
(Figure 4C).
Similar results were obtained in both skeletal muscle and brain
by using PJ34, a commercially available pan-PARP inhibitor
(Figures S3 and S4; Table S4).
DISCUSSION
The NAD+ pool is set by the balance between de novo
and salvage biosynthetic pathways and utilization by NAD+-
consuming enzymes. NAD+ is synthesized de novo from trypto-
phan, but the main source of NAD+ is from salvage pathways
(Houtkooper et al., 2010). These require the uptake of other
NAD+ precursors from the diet, including NR. Upon its entry in
the cell, NR is phosphorylated by NR kinases into nicotinamide
mononucleoside (NMN), which is then converted to NAD+ by
NMN adenylyltransferase (Bieganowski and Brenner, 2004).
NAD+ biosynthesis and cellular levels are also controlled by a
circadian clock related to the feeding/fasting cycle. For example,
in the mitochondrial compartment NAD+ levels regulate Sirtuin 3,
a deacetylase targeting respiratory chain subunits (Peek et al.,
2013), while in the nucleus NAD+ is a substrate of both Parp1
and Sirt. Parp1, the highest consumer of NAD+ inmammalian tis-
sues, is activated upon binding to damaged or abnormal DNA
(Durkacz et al., 1980) and catalyzes the formation of poly(ADP-
ribose) polymers (PAR) using NAD+ as a substrate, onto different
acceptor proteins, including Parp1 itself (Adamietz, 1987).
Ablation of the Parp1 gene, supplementation of NR or admin-
istration of Parp inhibitors (PARPi) can expand the NAD+ poolrs
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Figure 2. Effect of NR in Skeletal Muscle
(A) Treadmill analysis of motor performance. Solid black, vehicle-treated WT; dashed black, NR-treated WT; dashed red, vehicle-treated Sco2KOKI; solid red,
vehicle-treated Sco2KOKI; dashed red, NR-treated Sco2KOKI. Paired, two-tailed Student’s t test, **p < 0.01.
(B) NAD+ concentration in skeletal muscle. Solid black, vehicle-treated WT; black outline, NR-treated WT; solid red, vehicle-treated Sco2KOKI; red outline,
NR-treated Sco2KOKI. Error bars represent SD. Unpaired, two-tailed Student’s t test; *p < 0.05; **p < 0.01.
(C) Analysis of acetylation of FOXO1. (Upper panel) Representative western blot immunovisualization. (Lower panel) Densitometric analysis. Note that both WT
and Sco2KOKI samples showed reduced acetylation and increased total FOXO1 upon NR treatment, indicating activation of Sirt1. Tubulin was taken as loading
control. Color codes as in (B).
(D) Analysis of mRNA expression of FAO- and OXPHOS-related genes inSco2KOKI andWTmuscles of NR-treated and vehicle-treatedmice. Color codes as in (B).
Gene transcripts, retrotranscribed into cDNA, were normalized to theHprt gene transcript, taken as a standard, and expressed as time fold variation relative to the
WT. Error bars represent SD. Unpaired, two-tailed Student’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
(E) Western blot immunovisualization of COX1, COXVa, SDH 70KDa, Core 2, 39 KDa complex I subunit proteins in skeletal muscle of NR-treated and vehicle-
treated mice of the different genotypes. Note the increased amount of respiratory chain subunits in NR-treated Sco2KOKI samples.
(F) MRC activities (nmoles/min/mg of protein). Color codes as in (B). CS, citrate synthase; CI-IV, MRC complexes I–IV. Error bars represent SD. Unpaired, two-tail
Student’s t test; **p < 0.01; ***p < 0.001.
(G) COX staining in skeletal muscles of (Ga) vehicle-treated WT, (Gb) NR-treated WT, (Gc) vehicle-treated Sco2KOKI, and (Gd) NR-treated Sco2KOKI. Scale bar,
100 mm.
(H)mRNA expression analysis ofmtUPR genesHsp60,Clpp, andSod2 inSco2KOKI andWTmuscles of NR-treated and vehicle-treatedmice.Sod3was taken as a
non-mtUPR-related stress protein. Color codes as in (B). Gene transcripts, retrotranscribed into cDNA, were normalized to that of the Hprt gene transcript, taken
as a standard, and expressed as time fold variation relative to the WT. Error bars represent SD. Unpaired, two-tailed Student’s t test; **p < 0.01.
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In Vivo Correction of COX Deficiency by Sirt 1and activate sirtuins, particularly Sirt1, a master regulator of
mitochondrial homeostasis. These effects can protect mice
from high-fat (HF)-induced metabolic disease (Canto´ et al.,
2012). We have shown here that these treatments can correct
the biochemical and clinical phenotype of the Sco2KOKI mouse,
a model of genetically determined mitochondrial disease.Cell MIncreased transcription of genes related to both OXPHOS and
mtUPR was associated with activation of oxidative metabolism,
increase of mitochondrial respiratory chain activities, and
normalization of the endurance motor deficit, displayed by naive
Sco2KOKI animals. Notably, these effects were hardly seen inWT
littermates, suggesting that mitochondrial dysfunction sensitizesetabolism 19, 1042–1049, June 3, 2014 ª2014 The Authors 1045
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Figure 3. Effects of MRLB-45696 on the Skeletal Muscle
(A) Treadmill analysis of motor performance. Solid black, vehicle-treated WT; dashed black, MRLB-45696-treated WT; dashed red, vehicle-treated Sco2KOKI;
solid red, vehicle-treated Sco2KOKI; dashed red, MRLB-45696-treated Sco2KOKI. Paired, two-tailed Student’s t test; **p < 0.01.
(B) NAD+ concentration in skeletal muscle. Solid black, vehicle-treated WT; black outline, MRLB-45696-treated WT; solid red, vehicle-treated Sco2KOKI; red
outline, MRLB-45696-treated Sco2KOKI. Error bars represent SD. Unpaired, two-tailed Student’s t test; *p < 0.05.
(C) Analysis of acetylation of FOXO1. Both WT and Sco2KOKI samples showed reduced acetylation and increased total FOXO1 upon MRLB-45696 treatment,
indicating activation of Sirt1. Tubulin was taken as loading control. Densitometric analysis is presented in Table S3.
(D) mRNA expression analysis of FAO- and OXPHOS-related genes in Sco2KOKI and WT muscles of NR-treated and vehicle-treated mice. Solid black, vehicle-
treated WT; black outline, MRLB-45696-treated WT; solid red, vehicle-treated Sco2KOKI; red outline, MRLB-45696-treated Sco2KOKI. Gene transcripts, retro-
transcribed into cDNA, were normalized to the Hprt gene transcript, taken as a standard, and expressed as time fold variation relative to the WT. Error bars
represent SD. Unpaired, two-tailed Student’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
(E) Western blot immunovisualization of COX1, COXVa, SDH 70KDa, Core 2, 39 KDa complex I subunit proteins in skeletal muscle of MRLB-45696-treated and
vehicle-treated mice of the different genotypes. Note the increased amount of respiratory chain subunits in MRLB-45696-treated Sco2KOKI samples.
(F) Respiratory chain activities (nmoles/min/mg of protein). Color codes as in (B). CS, citrate synthase; CI-IV, MRC complexes I–IV. Error bars represent SD.
Unpaired, two-tailed Student’s t test; **p < 0.01; ***p < 0.001.
(G) COX staining in skeletal muscles of (Ga) vehicle-treated WT, (Gb) MRLB-45696-treated WT, (Gc) vehicle-treated Sco2KOKI, and (Gd) MRLB-45696-treated
Sco2KOKI. Scale bar, 100 mm.
(H) mRNA expression analysis of mtUPR genesHsp60,Clpp, and Sod2 in Sco2KOKI andWTmuscles of MRLB-45696-treated and vehicle-treated mice. Sod3was
takenas a non-mtUPR related stress protein.Color codesas in (B). The levels of thegene transcripts, retrotranscribed into cDNA,were normalized to that of theHprt
gene transcript, taken as a standard, and expressed as time fold variation relative to theWT. Error bars represent SD. Unpaired, two-tail Student’s t test; **p < 0.01.
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driogenic programs. Increased mitochondrial function can be
achieved in WT animals only by much longer-term treatments
(>6 months) (Pirinen et al., 2014).
In contrast with previous results, we found no change in
mtDNA copy number and CS activity in NR- or PARPi-treated1046 Cell Metabolism 19, 1042–1049, June 3, 2014 ª2014 The Authoversus untreated animals, possibly because of the shorter time-
frame of our experimental protocol (4 weeks) compared to that
of other studies (12 weeks). This observation suggests time-
dependent activation of different mitochondriogenic programs,
with induction of OXPHOS- and FAO-related genes occurring
much earlier than stimulation of mitochondrial proliferation andrs
Figure 4. Effect of MRLB-45696 in the Brain
(A) mRNA expression analysis in the brain. Solid
black, vehicle-treated WT; black outline, MRLB-
45696-treated WT; solid red, vehicle-treated
Sco2KOKI; red outline, MRLB-45696-treated
Sco2KOKI.
(B) Respiratory chain activities (nmoles/min/mg of
protein). Color codes as in (A). CS, citrate syn-
thase; CI-IV, MRC complexes I–IV. Error bars
represent SD. The asterisks represent the signifi-
cance levels calculated by unpaired, two-tailed
Student’s t test; **p < 0.01; ***p < 0.001.
(C) COX staining in the brain of MRLB-45696
treated and vehicle-treated Sco2KOKI and WT
mice. The arrows indicate Purkinje cells showing
increased COX activity. Scale bar, 100 mm.
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tation up to 6 months induced mitochondrial biogenesis in the
brain and improvement of cognitive dysfunction of an Alzheimer
disease mouse model (Gong et al., 2013). While we observed
hardly any effect of NR in our 4 week trial, two pan-PARP inhib-
itors did correct the respiratory chain defect in the brains of our
Sco2KOKI mice. This observation is particularly relevant, as the
brain is an exquisite target of mitochondrial dysfunction, and
progressive encephalopathy is themost frequent clinical presen-
tation of mitochondrial disease in infancy and childhood.
Our work supports the idea that the increase of NAD+ levels in
critical tissues is an effective therapeutic option for mitochon-
drial disease. NR is a natural vitamin with no known adverse ef-
fects, which could be administered as a dietary supplement,
particularly in case of isolated mitochondrial myopathy. Our re-
sults are concordant with very recent works reporting beneficial
effects of NAD+ precursors in mouse models characterized by
reduced NAD+/NADH ratio, such as aging (Gomes et al., 2013)
or complex I deficiency (Karamanlidis et al., 2013).
The therapeutic potential of Parp inhibitors has recently
attracted much interest. Initially shown to boost oxidative
metabolism in diet-induced models of obesity, Parp1 ablation
or inhibition has recently been reported to remarkably rescue
pharmacological models of liver cirrhosis, partly by correcting
the associated mitochondrial impairment (Mukhopadhyay
et al., 2013). Several PARP inhibitors are currently under clinical
trial as anticancer molecules, and seem to be associated with
relatively mild side effects (Bundred et al., 2013; Tutt et al.,
2010). However, more work is needed to evaluate their use in
chronic conditions such as primary mitochondrial disorders in
view of their potential genotoxic effects.
EXPERIMENTAL PROCEDURES
Western Blot Analysis
Mouse tissues were homogenized in 15 volumes of 10 mM potassium
phosphate buffer (pH 7.5). Mitochondrial-enriched fractions were collectedCell Metabolism 19, 1042–10after centrifugation at 800 g for 10 min in
the presence of protease inhibitors, and frozen
and thawed three times in liquid nitrogen.
Protein concentration was determined by the
Lowry method. Aliquots, 70 mg each, were run
through a 12% SDS-PAGE and electroblottedonto a nitrocellulose membrane, which was then matched with different
antibodies.
In Vivo Experiments
Animal studies were approved by the Ethics Committee of the Foundation
‘‘Carlo Besta’’ Neurological Institute, in accordance with guidelines of the
Italian Ministry of Health. The use and care of animals followed the Italian
Law D.L. 116/1992 and the EU directive 86/609/CEE. Mice were maintained
in a temperature- and humidity-controlled animal-care facility, with a 12 hr
light/dark cycle and free access to water and food. Animals were sacrificed
by cervical dislocation.
Locomotor Analysis
A standard treadmill apparatus (Columbus Instruments, Columbus, OH) was
used tomeasuremotor exerciseendurance,asdescribed inViscomiet al. (2011)
Morphological Analysis
For histochemical analysis, tissues were frozen in liquid-nitrogen precooled
isopentane. Series of 8 mm thick sections were stained for COX and SDH, as
described (Sciacco and Bonilla, 1996).
Biochemical Analysis of MRC Complexes
Muscle quadriceps samples stored in liquid nitrogen were homogenized in
10 mM phosphate buffer (pH 7.4), and the spectrophotometric activity of cI,
cII, cIII, and cIV, as well as CS, was measured as described (Bugiani et al.,
2004). Note that in all panels the activity of cII has been multiplied by 10
for visualization clarity.
NAD+ Determination
NAD+ was extracted using acidic and alkaline extraction methods, respec-
tively (Yang and Sauve, 2006). Tissue NAD+ was analyzed with mass spec-
trometry as previously described (Yang and Sauve, 2006).
Real-Time PCR
MtDNA content and transcripts analysis was carried out by SYBR Green real-
time PCR, as described (Viscomi et al., 2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article at http://dx.
doi.org/10.1016/j.cmet.2014.04.001.49, June 3, 2014 ª2014 The Authors 1047
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